Beta-Adrenergic Antagonists in the Treatment of Glaucoma

Abstract

Purpose Beta-blockers have been used since the late 1970's as ‘first-choice’ in the treatment for glaucoma. Since the introduction of new molecules in clinical routine, the current role of beta-blockers in glaucoma therapy has been rediscussed. In particular, concerns have been raised regarding their actual safety profile. Methods This review will focus on the latest advances on the efficacy and safety profiles of non-selective beta-blockers. Conclusions The data provided will help to trace a more appropriate role for beta-blockers in glaucoma therapy.